Cart
sales@molnova.com
IACS-52825
CAS No. 2640376-72-1
IACS-52825( —— )
Catalog No. M37232 CAS No. 2640376-72-1
IACS-52825 is a selective and potent dual leucine zipper kinase (DLK) inhibitor that reverses para-mechanical aberrant pain in a CIPN mouse model for the study of neurological disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 459 | In Stock |
|
| 10MG | 657 | In Stock |
|
| 25MG | 1026 | In Stock |
|
| 50MG | 1386 | In Stock |
|
| 100MG | 1832 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIACS-52825
-
NoteResearch use only, not for human use.
-
Brief DescriptionIACS-52825 is a selective and potent dual leucine zipper kinase (DLK) inhibitor that reverses para-mechanical aberrant pain in a CIPN mouse model for the study of neurological disorders.
-
DescriptionIACS-52825 is a potent and selective DLK inhibitor with Kd of 1.3 nM, useful for the study of chemotherapy-induced peripheral neuropathy.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorDNA Alkylation
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2640376-72-1
-
Formula Weight426.29
-
Molecular FormulaC16H13F7N4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@@H](C(F)(F)F)(O)C=1N(C23CC(F)(C2)C3)C=C(N1)C=4C=C(OC(F)(F)F)C(N)=NC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kang Le, et al. Discovery of IACS-52825, a Potent and Selective DLK Inhibitor for Treatment of Chemotherapy-Induced Peripheral Neuropathy. J Med Chem. 2023 Jul 27;66(14):9954-9971. ?
molnova catalog
related products
-
6,6-Di-O-sinapoylsuc...
6,6'-Di-O-sinapoylsucrose is a sucrose ester hat can be found in cynanchum amplexicaule.
-
(E)-3-(2-Methoxyphen...
(E)-3-(2-Methoxyphenyl)acrylaldehyde
-
Manzamine A
Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1.
